Trials / Completed
CompletedNCT00768859
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- The Netherlands Cancer Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the activity of the combination of paclitaxel, trastuzumab and carboplatin as neo-adjuvant treatment in patients with stage II or III HER2 positive breast cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | paclitaxel, trastuzumab and carboplatin | paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3 |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2011-08-01
- Completion
- 2012-05-01
- First posted
- 2008-10-08
- Last updated
- 2012-05-11
Locations
9 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT00768859. Inclusion in this directory is not an endorsement.